keyword
MENU ▼
Read by QxMD icon Read
search

antibody-drug conjugates

keyword
https://www.readbyqxmd.com/read/28727765/defining-the-target-and-the-effect-of-imatinib-on-the-filarial-c-abl-homologue
#1
Elise M O'Connell, Olena Kamenyeva, Sara Lustigman, Aaron Bell, Thomas B Nutman
BACKGROUND: Previously we demonstrated the micro- and macrofilaricidal properties of imatinib in vitro. Here we use electron and multiphoton microscopy to define the target of imatinib in the adult and microfilarial stages of Brugia malayi, and assess the effects of pharmacologically relevant levels of imatinib on the adult parasites. METHODS: After fixation of adult B. malayi males and females, sections were stained with polyclonal rabbit anti-c-Abl antibody (or isotype control) and imaged with multiphoton fluorescent microscopy...
July 20, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28727448/extensive-survey-of-antibody-invariant-positions-for-efficient-chemical-conjugation-using-expanded-genetic-codes
#2
Akifumi Kato, Mitsuo Kuratani, Tatsuo Yanagisawa, Kazumasa Ohtake, Akiko Hayashi, Yoshimi Amano, Kaname Kimura, Shigeyuki Yokoyama, Kensaku Sakamoto, Yasuhisa Shiraishi
The site-specific chemical conjugation of proteins, following synthesis with an expanded genetic code, promises to advance antibody-based technologies, including antibody drug conjugation and the creation of bispecific Fab dimers. The incorporation of non-natural amino acids into antibodies not only guarantees site specificity but also allows the use of bio-orthogonal chemistry. However, the efficiency of amino acid incorporation fluctuates significantly among different sites, thereby hampering the identification of useful conjugation sites...
July 20, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/28722110/renal-infiltrating-cd11c-cells-are-pathogenic-in-murine-lupus-nephritis-through-promoting-cd4-t-cell-responses
#3
Xiaofeng Liao, Jingjing Ren, Alec Reihl, Tharshikha Pirapakaran, Bharath Sreekumar, Thomas E Cecere, Christopher M Reilly, Xin M Luo
Lupus nephritis (LN) is a major manifestation of systemic lupus erythematosus (SLE) causing morbidity and mortality in 40-60% of SLE patients. The pathogenic mechanisms of LN are not completely understood. Recent studies have demonstrated the presence of various immune cell populations in lupus nephritic kidneys of both SLE patients and lupus-prone mice. These cells may play important pathogenic or regulatory roles in situ to promote or sustain LN. Here, using lupus-prone mouse models, we showed the pathogenic role of a kidney-infiltrating CD11c(+) myeloid cell population in LN...
July 19, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28715775/evolution-of-anti-her2-therapies-for-cancer-treatment
#4
REVIEW
Sagun Parakh, Hui K Gan, Adam C Parslow, Ingrid J G Burvenich, Antony W Burgess, Andrew M Scott
The development of HER2-directed monoclonal antibodies and tyrosine kinase inhibitors have provided benefits to cancer patients, as well as produced many insights into the biology of the ErbB receptor family. Current therapies based on ErbB family members have resulted in improved overall survival with associated improvements in quality of life for the cancer patients that respond to treatment. Compared to monotherapy using either two antibodies to block the HER2 receptor blockade or combinatorial approaches with HER2 antibodies and standard therapies has provided additional benefits...
July 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28703284/brentuximab-vedotin-in-cd30-cutaneous-lymphoma-how-do-we-treat-how-shall-we-treat-a-review-of-the-literature
#5
REVIEW
R Stranzenbach, E Dippel, M Schlaak, R Stadler
Brentuximab vedotin is an antibody-drug conjugate that brings the antimicrotubule agent monomethyl auristatin E into CD30-expressing cells. Some prior studies could demonstrate good efficacy in cutaneous lymphomas. The standard therapeutic scheme is 1.8mg/kg every 3 weeks. Background of this work is the fact that cutaneous lymphoma has a different pathophysiology, and a dynamic other than systemic lymphoma. The objectives of this review were to get an overview of the currently used therapeutic regimen, and to check whether dose reduction or modified time intervals could benefit in a similar activity with less toxicity...
July 13, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28699537/recent-advances-in-polymeric-nanosystems-for-treating-cutaneous-melanoma-and-its-metastasis
#6
Yi-Ping Chou, Yin-Ku Lin, Chun-Han Chen, Jia-You Fang
Melanoma shows a high possibility of mortality after it metastasizes because of its aggressive nature. Although there are several options for anti-melanoma therapy, this skin malignancy is resistant to some therapies. Chemotherapy, biochemotherapy, immunotherapy, and adoptive cell therapy have failed to exhibit a significant amelioration in overall survival. Nanomedicine provides an opportunity to improve the efficiency of the anti-melanoma regimen. Nanoparticles for treating melanoma provide the advantages over conventional therapies such as drug solubility increment, drug stability enhancement, epithelium permeability and bioavailability amelioration, half-life prolonging, tumor targeting, and side effect minimization...
July 10, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28688987/tumor-targeting-by-lentiviral-vectors-combined-with-magnetic-nanoparticlesin-mice
#7
Ester Borroni, Marta Miola, Sara Ferraris, Giulia Ricci, Kristina ŽužekRožman, Nina Kostevšek, Angela Catizone, Lia Rimondini, Maria Prat, Enrica Verné, Antonia Follenzi
Nanomaterials conjugated or complexed with biological moieties such as antibodies, polymers or peptides appear to be suitable not only for drug delivery but also for specific cancer treatment. Here, biocompatible iron oxide magnetic nanoparticles (MNPs) with or without a silica shell coupled with lentiviral vectors (LVs) are proposed as a combined therapeutic approach to specifically target gene expression in a cancer mouse model. Initially, four different MNPs were synthesized and their physical properties were characterized to establish and discriminate their behaviors...
July 5, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28688616/current-possibilities-of-liquid-chromatography-for-the-characterization-of-antibody-drug-conjugates
#8
REVIEW
Balázs Bobály, Sandrine Fleury-Souverain, Alain Beck, Jean-Luc Veuthey, Davy Guillarme, Szabolcs Fekete
Antibody Drug Conjugates (ADCs) are innovative biopharmaceuticals gaining increasing attention over the last two decades. The concept of ADCs lead to new therapy approaches in numerous oncological indications as well in infectious diseases. Currently, around 60 CECs are in clinical trials indicating the expanding importance of this class of protein therapeutics. ADCs show unprecedented intrinsic heterogeneity and address new quality attributes which have to be assessed. Liquid chromatography is one of the most frequently used analytical method for the characterization of ADCs...
June 24, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28687619/resistance-to-the-antibody-drug-conjugate-t-dm1-is-based-in-a-reduction-in-lysosomal-proteolytic-activity
#9
Carla Ríos-Luci, Sara García-Alonso, Elena Díaz-Rodríguez, Mercedes Nadal-Serrano, Joaquin Arribas, Alberto Ocaña, Atanasio Pandiella
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved recently to treat HER2+ breast cancers. Despite its impressive clinical efficacy in many patients, intrinsic and acquired resistance to T-DM1 has emerged as a challenge. To identify mechanisms of T-DM1 resistance, we isolated several resistant HER2+ clones exhibiting stable drug refractoriness in vitro and in vivo. Genomic comparisons showed substantial differences among three of the isolated clones, indicating several potential mechanisms of resistance to T-DM1...
July 7, 2017: Cancer Research
https://www.readbyqxmd.com/read/28681884/condition-responsive-nanoparticles-for-managing-infection-and-inflammation-in-keratitis
#10
Saad M Ahsan, Ch Mohan Rao
Keratitis is a major cause of avoidable visual impairment. About 30% of patients with fungal keratitis eventually become permanently blind in the developing world. Proteases, secreted by the pathogen and the host, damage the cornea before the infection is resolved. Treating keratitis is a challenge because both infection and inflammation need to be addressed. An additional challenge is to maintain a therapeutic dose at the corneal surface as blinking and tear film wash away the drugs, administered as eye drops...
July 20, 2017: Nanoscale
https://www.readbyqxmd.com/read/28679774/syd985-a-novel-duocarmycin-based-her2-targeting-antibody-drug-conjugate-shows-antitumor-activity-in-uterine-and-ovarian-carcinosarcoma-with-her2-neu-expression
#11
Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan D Black, Federica Predolini, Francesca Pettinella, Alice Masserdotti, Luca Zammataro, Gary Altwerger, Natalia Buza, Pei Hui, Serena Wong, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz, Alessandro D Santin
Purpose: Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements with heterogeneous HER2/neu expression. We compared the efficacy of SYD985, (Synthon Biopharmaceuticals BV), a novel HER2-targeting antibody-drug conjugate (ADC), to Trastuzumab emtansine (T-DM1, Genentech-Roche) against primary uterine and ovarian CS. <p>Experimental Design: Eight primary CS cell lines were evaluated for HER2/neu surface expression by IHC and gene amplification by FISH assays...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28679770/therapy-of-small-cell-lung-cancer-sclc-with-a-topoisomerase-i-inhibiting-antibody-drug-conjugate-adc-targeting-trop-2-sacituzumab-govitecan
#12
Jhanelle E Gray, Rebecca S Heist, Alexander N Starodub, D Ross Camidge, Ebenezer A Kio, Gregory A Masters, W Thomas Purcell, Michael J Guarino, Jamal Misleh, Charles J Schneider, Bryan J Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A Messersmith, Serengulam V Govindan, Pius P Maliakal, Boyd Mudenda, William A Wegener, Robert M Sharkey, David M Goldenberg
Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small-cell lung cancer (mSCLC) patients. <p>Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1-7) mSCLC who received either 8 or 10 mg/kg i.v. on days 1 and 8 of 21-day cycles. The primary endpoints were safety and objective response rate (ORR); duration of response, progression-free survival (PFS), and overall survival (OS) were secondary endpoints.</p> <p>Results: Sixty percent of patients showed tumor shrinkage from baseline CTs...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28677631/macromolecular-conjugate-and-biological-carrier-approaches-for-the-targeted-delivery-of-antibiotics
#13
REVIEW
Nhan Dai Thien Tram, Pui Lai Rachel Ee
For the past few decades, the rapid rise of antibiotic multidrug-resistance has presented a palpable threat to human health worldwide. Meanwhile, the number of novel antibiotics released to the market has been steadily declining. Therefore, it is imperative that we utilize innovative approaches for the development of antimicrobial therapies. This article will explore alternative strategies, namely drug conjugates and biological carriers for the targeted delivery of antibiotics, which are often eclipsed by their nanomedicine-based counterparts...
July 4, 2017: Antibiotics
https://www.readbyqxmd.com/read/28677116/ds-8201a-a-new-her2-targeting-antibody-drug-conjugate-incorporating-a-novel-dna-topoisomerase-i-inhibitor-overcomes-her2-positive-gastric-cancer-t-dm1-resistance
#14
Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, Kazuko Sakai, Osamu Maenishi, Yusuke Ogitani, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa, Junji Tsurutani
Anti-HER2 therapies are beneficial for patients with HER2-positive breast or gastric cancer. T-DM1 is a HER2-targeting antibody-drug conjugate (ADC) comprising the antibody trastuzumab, a linker, and the tubulin inhibitor DM1. Although effective in treating advanced breast cancer, all patients eventually develop T-DM1 resistance. DS-8201a is a new ADC incorporating an anti-HER2 antibody, a newly developed, enzymatically cleavable peptide linker, and a novel, potent, exatecan-derivative topoisomerase I inhibitor (DXd)...
July 5, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28675164/antibody-drug-conjugates-in-glioblastoma-therapy-the-right-drugs-to-the-right-cells
#15
REVIEW
Hui K Gan, Martin van den Bent, Andrew B Lassman, David A Reardon, Andrew M Scott
Glioblastomas are high-grade brain tumours with a poor prognosis and, currently, few available therapeutic options. This lack of effective treatments has been linked to diverse factors, including target selection, tumour heterogeneity and poor penetrance of therapeutic agents through the blood-brain barrier and into tumours. Therapies using monoclonal antibodies, alone or linked to cytotoxic payloads, have proved beneficial for patients with different solid tumours; these approaches are currently being explored in patients with glioblastoma...
July 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28674294/antibody-therapeutics-bench-to-bedside
#16
Chie Sakanaka
 Monoclonal antibodies have been considered promising therapeutic entities due to their highly specific binding to antigens. For oncology in particular, the tumor specific binding of an antibody, without affecting normal tissue, is considered an ideal cancer therapy. Although the proposed mechanism of action of antibody therapeutics varies by targets and indications, antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), ligand neutralization and inhibition of the signaling pathway are commonly used...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/28668224/the-future-of-cysteine-cathepsins-in-disease-management
#17
REVIEW
Lovro Kramer, Dušan Turk, Boris Turk
Since the discovery of the key role of cathepsin K in bone resorption, cysteine cathepsins have been investigated by pharmaceutical companies as drug targets. The first clinical results from targeting cathepsins by activity-based probes and substrates are paving the way for the next generation of molecular diagnostic imaging, whereas the majority of antibody-drug conjugates currently in clinical trials depend on activation by cathepsins. Finally, cathepsins have emerged as suitable vehicles for targeted drug delivery...
June 28, 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/28665214/the-evolving-role-of-targeted-drugs-in-the-treatment-of-hodgkin-lymphoma
#18
Dennis A Eichenauer, Andreas Engert
Hodgkin lymphoma (HL) is a B-cell-derived malignancy mostly affecting young adults. More than 80% of patients are cured after stage-adapted first-line treatment with chemotherapy and/or radiotherapy. About 50% of patients with disease recurrence achieve long-term remission with second-line treatment consisting of high-dose chemotherapy and autologous stem cell transplantation. However, HL treatment is often associated with acute toxicity and in part life-threatening late effects. Implementing targeted drugs may reduce toxicity and potentially further optimize efficacy...
July 10, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28664386/novel-therapies-for-acute-myeloid-leukemia-are-we-finally-breaking-the-deadlock
#19
REVIEW
Maximilian Stahl, Benjamin Y Lu, Tae Kon Kim, Amer M Zeidan
Acute myeloid leukemia (AML) is one of the best studied malignancies, and significant progress has been made in understanding the clinical implications of its disease biology. Unfortunately, drug development has not kept pace, as the '7+3' induction regimen remains the standard of care for patients fit for intensive therapy 40 years after its first use. Temporal improvements in overall survival were mostly confined to younger patients and driven by improvements in supportive care and use of hematopoietic stem cell transplantation...
June 29, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28662334/protease-cleavable-linkers-modulate-the-anticancer-activity-of-noninternalizing-antibody-drug-conjugates
#20
Alberto Dal Corso, Samuele Cazzamalli, Rémy Gébleux, Martin Mattarella, Dario Neri
Antibody-drug conjugates (ADCs) represent an attractive class of biopharmaceutical agents, with the potential to selectively deliver potent cytotoxic agents to tumors. It is generally assumed that ADC products should preferably bind and internalize into cancer cells in order to liberate their toxic payload, but a growing body of evidence indicates that also ADCs based on noninternalizing antibodies may be potently active. In this Communication, we investigated dipeptide-based linkers (frequently used for internalizing ADC products) in the context of the noninternalizing F16 antibody, specific to a splice isoform of tenascin-C...
July 19, 2017: Bioconjugate Chemistry
keyword
keyword
73679
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"